Lioulios G, Stangou M, Sarafidis PA, et al. - Researchers focused on the longstanding impacts of sucroferric oxyhydroxide [SOH; an iron-based phosphate binder (PB)] on the anemia as well as iron indices in patients on dialysis in this observational analysis. This study involved 110 patients from 3 dialysis centers, including 49 receiving chronic treatment with SOH (cohort A), while 61 either taking other PB or no treatment for hyperphosphatemia (cohort B). This study included phase I and phase II. The observed hemoglobin, ferritin and transferrin saturation, serum phosphate concentration, and intact PTH did not differ statistically significantly between 2 cohorts. Cohort A vs cohort B demonstrated marginally, but significantly higher calcium levels. In phase II, there were no significant alterations in hematological parameters following a 6-month treatment with SOH. During this time, no significant alterations were evident in the administration of iron supplements or erythropoietin dose. Findings revealed the effectiveness of SOH. Experts noted that its long-term use was not complicated by iron overload.